Novavax to Participate in Jefferies London Healthcare Conference

News provided by

Nov 10, 2023, 09:25 ET

GAITHERSBURG, Md., Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Conference Details:
Fireside Chat
Date:		Wednesday, November 15, 2023
Time:		9:00 – 9:25 a.m. Greenwich Mean Time (GMT)
Location:		London
Moderator:		Roger Song, M.D., CFA, Equity Analyst
Novavax participants:		John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development

Conference
Event:		Investor Meetings
Date:		Wednesday, November 15, 2023

Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]

Media
Ali Chartan
240-720-7804
[email protected]

SOURCE NOVAVAX, INC